-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Managing anemia in patients with chronic heart failure: what do we know?
Review
(3147) Views (1342) Full article downloads
Authors: Ankur Sandhu, Sandeep Soman, Michael Hudson, et al
Published Date April 2010
Volume 2010:6 Pages 237 - 252
DOI: http://dx.doi.org/10.2147/VHRM.S4619
Ankur Sandhu1, Sandeep Soman1, Michael Hudson2, Anatole Besarab1
1Divisions of Nephrology, 2Cardiology, Henry Ford Health System, Detroit, Michigan, USA
Abstract: Anemia is common in patients with chronic heart failure (HF) with an incidence ranging from 4% to 55% depending on the studied population. Several studies have highlighted that the prevalence of anemia increases with worsening heart failure as reflected by New York Heart Association classification. Additionally, several epidemiological studies have highlighted its role as a prognostic marker, linking it to worse outcomes including; malnutrition, increased hospitalizations, refractory heart failure and death. The pathophysiology of anemia is multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated renal insufficiency. There are a host of epidemiological studies examining HF outcomes and anemia, but only a few randomized trials addressing this issue. The purpose of this article is to review the literature that examines the interrelationship of anemia and congestive HF, analyzing its etiology, impact on outcomes and also the role of associated kidney disease as well as cardiorenal syndrome both as a marker of morbidity and mortality.
Keywords: anemia, cardio-renal syndrome, heart failure
Readers of this article also read:
Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Comparison of linear–stochastic and nonlinear–deterministic algorithms in the analysis of 15-minute clinical ECGs to predict risk of arrhythmic death
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update
Optimizing blood pressure control through the use of fixed combinations
Optimal management of iron deficiency anemia due to poor dietary intake
Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium
Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




